Closed system switch units (CSTDs) have been used with hazardous medication for a number of a long time. The aim of this whitepaper is to extend consciousness amongst healthcare professionals, gadget producers, regulators, and pharmaceutical/biotech firms on the potential points round the usage of CSTDs with biologics drug merchandise to permit their knowledgeable use in clinics. Particularly, we focus on the important thing matters associated to the usage of CSTDs with biologics merchandise, together with elements and supplies of building, a breakdown of regulatory, technical, and medical site-related dangers and challenges related to the usage of CSTDs with organic merchandise, gathered from stakeholder dialogue on the IQ Working Group convention, and concerns on present testing necessities and communication methods to drive additional dialog on the suitable use of CSTDs.
Given the technical challenges of utilizing CSTDs with biologics, coupled with the present rules surrounding CSTD approval and correct use, in addition to a necessity for alignment and standardization to allow a constant technique for compatibility testing and communication of incompatibilities, it is strongly recommended that world well being authorities and different stakeholders search to know these points, with a view to alleviate these issues and hold healthcare staff and sufferers secure from hurt.
First Report of Anthracnose of Papaya (Carica papaya L.) Attributable to Colletotrichum siamense in China
Papaya (Carica papaya L.) is a rosaceous plant broadly grown in China, which is economically vital. Anthracnose attributable to Colletotrichum sp. is a crucial postharvest illness, which severely impacts the standard of papaya fruits (Liu et al., 2019). Throughout April 2020, some mature papaya fruits with typical anthracnose signs had been noticed in Fusui, Nanning, Guangxi, China with a mean of 30% illness incidence (DI) and over 60% DI in some orchards. Preliminary signs of those papayas appeared as watery lesions, which turned darkish brown, sunken, with a conidial mass showing on the lesions below humid and heat circumstances.
The illness severity different amongst fruits, with some displaying tiny mild brown spots, and a few ripe fruits presenting brownish, rounded, necrotic and depressed lesions over a part of their floor. Samples from two papaya plantations (107.54°E, 22.38°N) had been collected, and delivered to the laboratory. Symptomatic diseased tissues had been minimize into 5 × 5 mm items, floor sterilized with 2% (v/v) sodium hypochlorite for 1 minute, and rinsed thrice with sterilized water. The items had been then positioned on potato dextrose agar (PDA). After incubation at 25°C in the dead of night for one week, colonies with uniform morphology had been obtained. The aerial mycelium on PDA was white on high facet, and concentric rings of salmon acervuli on the underside.
A gelatinous layer of spores was noticed on a part of PDA plates after 7 days at 28°C. The conidia had been elliptical, aseptate and hyaline (Zhang et al., 2020). The size and width of 60 conidia had been measured for every of the 2 consultant isolates, MG2-1 and MG3-1, and these averaged 13.10 × 5.11 μm and 14.45 × 5.95 μm. DNA was extracted from mycelia of those two isolates with the DNA safe Plant Equipment (TIANGEN, Biotech, China). The interior transcribed spacer (ITS), partial actin (ACT), calmodulin (CAL), chitin synthase (CHS), β-tubulin 2 (TUB2) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) areas had been amplified by PCR and sequenced. The sequences had been deposited into GenBank with accessions MT904003, MT904004, and MT898650 to MT898659.
BLASTN analyses towards the GenBank database confirmed that all of them had over 99% id to the kind pressure of Colletotrichum siamense isolate ICMP 18642 (GenBank accession numbers JX010278, GQ856775, JX009709, GQ856730, JX010410, JX010019) (Weir et al., 2012). A phylogenetic tree primarily based on the mixed ITS, ACT, CAL, CHS, TUB2 and GAPDH sequences utilizing the Neighbor-joining algorithm additionally confirmed that the isolates had been C. siamense. Pathogenicity checks had been carried out on 24 mature, wholesome and surface-sterilized papaya fruits. On 12 papaya fruits, three nicely separated wounded websites had been made for inoculation, and for every wounded web site, six adjoining pinhole wounds had been made in a 5-mm-diameter round space utilizing a sterilized needle. A 10 µl aliquot of 1 × 106 conidia/ml suspension of every of the isolates (MG2-1 and MG3-1) was inoculated into every wound. For every isolate, there have been six replicate fruits.
The management fruits had been inoculated with sterile distilled water. The identical inoculation was utilized to 12 non-wound papaya fruits. Fruits had been then positioned in containers which had been first washed with 75% alcohol and lined with autoclaved filter paper moistened with sterilized distilled water to keep up excessive humidity. The containers had been then sealed and incubated at 28°C. After 10 days, all of the inoculated fruits confirmed signs, whereas the fruits that had been mock inoculated had been with out signs. Koch’s postulates had been fulfilled by re-isolation of C. siamense from diseased fruits. To our data, that is the primary report of C. siamense inflicting anthracnose of papaya in China. This discovering will allow higher management of anthracnose illness attributable to C. siamense on papaya.

Precision Regulation Method: A COVID-19 Triggered Regulatory Drive in South Korea
COVID-19 has triggered numerous adjustments in our on a regular basis lives and the way we conceptualize the capabilities of governments. Some areas require stricter types of regulation whereas others name for deregulation. The problem for the regulatory authorities is to handle these doubtlessly conflicting calls for in regulation and outline coherently their total regulatory rationale. The precision regulation strategy generally is a useful strategy. It’s outlined right here as a streamlined strategy to regulation to ship the proper strategies of regulation for the proper group of individuals on the proper time.
PB antibody |
70R-2192 |
Fitzgerald |
50 ug |
EUR 467 |
Description: Rabbit polyclonal PB antibody raised against the middle region of Pb |
Cellufine PB |
683-986-326 |
JNC America |
50 ml |
Ask for price |
Cellufine PB |
683-986-328 |
JNC America |
500 ml |
Ask for price |
Cellufine PB |
683-986-330 |
JNC America |
5 lt |
Ask for price |
Cellufine PB |
683-986-335 |
JNC America |
10 lt |
Ask for price |
Pseudoproto-Pb |
TBW00844 |
ChemNorm |
unit |
Ask for price |
PB Cadherin Antibody |
47938-100ul |
SAB |
100ul |
EUR 252 |
PB Blocking Peptide |
33R-2067 |
Fitzgerald |
100 ug |
EUR 180 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of pb antibody, catalog no. 70R-2192 |
PB 28 dihydrochloride |
B7107-10 |
ApexBio |
10 mg |
EUR 284 |
PB 28 dihydrochloride |
B7107-50 |
ApexBio |
50 mg |
EUR 1038 |
PB Cadherin Blocking Peptide |
20-abx162098 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
PB Cadherin Conjugated Antibody |
C47938 |
SAB |
100ul |
EUR 397 |
electrolyte galv.o2/pb electr., 125ml |
B151 |
Consort |
ea |
EUR 48 |
membranes+electrolyte for o2/pb electr |
SZ02K |
Consort |
ea |
EUR 138 |
Pituitary And Brain Cadherin (PB Cadherin) Antibody |
20-abx133389 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
- Shipped within 5-10 working days.
|
PB-CMV-GreenPuro Scramble Hairpin Control Vector |
PBSI505-000PA-1 |
SBI |
10 ug |
EUR 689 |
- Category: PiggyBac Technology
|
PB-CMV-MCS-EF1-Puro cDNA cloning and expression vector |
PB510B-1 |
SBI |
10 ug |
EUR 702 |
- Category: PiggyBac Technology
|
PB-CMV-MCS-EF1-GFP cDNA cloning and expression vector |
PB511B-1 |
SBI |
10 ug |
EUR 702 |
- Category: PiggyBac Technology
|
PB-CMV-MCS-EF1-RFP cDNA cloning and expression vector |
PB512B-1 |
SBI |
10 ug |
EUR 702 |
- Category: PiggyBac Technology
|
PB-CMV-MCS-EF1-GreenPuro cDNA cloning and expression vector |
PB513B-1 |
SBI |
10 ug |
EUR 702 |
- Category: PiggyBac Technology
|
PB-CMV-MCS-EF1-RedPuro cDNA Cloning and Expression Vector |
PB514B-2 |
SBI |
10 ug |
EUR 702 |
- Category: PiggyBac Technology
|
PB-EF1-MCS-IRES-GFP cDNA cloning and expression vector |
PB530A-2 |
SBI |
10 ug |
EUR 702 |
- Category: PiggyBac Technology
|
PB-EF1-MCS-IRES-RFP cDNA Cloning and Expression Vector |
PB531A-2 |
SBI |
10 ug |
EUR 702 |
- Category: PiggyBac Technology
|
PB-EF1-MCS-IRES-Neo cDNA cloning and expression vector |
PB533A-2 |
SBI |
10 ug |
EUR 702 |
- Category: PiggyBac Technology
|
PB-MSCV-MCS-EF1-GreenPuro cDNA Cloning and Expression Vector |
PB713B-1 |
SBI |
10 ug |
EUR 702 |
- Category: PiggyBac Technology
|
PB-CMV-GreenPuro-H1-MCS shRNA cloning and expression vector |
PBSI505A-1 |
SBI |
10 ug |
EUR 702 |
- Category: PiggyBac Technology
|
PB-EF1-GreenPuro-H1-MCS shRNA cloning and expression vector |
PBSI506A-1 |
SBI |
10 ug |
EUR 702 |
- Category: PiggyBac Technology
|
piggyBac-HR with GFP+Puro markers and TK selection [MCS1-5'PB TR-EF1?-GFP-T2A-Puro-T2A-hsvTK-pA-3' PB TR-MCS2] for Gene Correction |
PBHR100A-1 |
SBI |
10 ug |
EUR 1334 |
|
PB-Cuo-miR-302/367-IRES-GFP-EF1-CymR-Puro Inducible iPSC Vector |
PBQM-MIR302 |
SBI |
10 ug |
EUR 2022 |
- Category: PiggyBac Technology
|
PB-EF1a-Oct4-Sox2-Klf4-Myc-IRES-GFP Human 4-in-1 iPSC Vector |
PB630A-1 |
SBI |
10 ug |
EUR 1674 |
- Category: PiggyBac Technology
|
PB-Cuo-MCS-IRES-GFP-EF1-CymR-Puro Inducible cDNA Cloning and Expression Vector |
PBQM812A-1 |
SBI |
10 ug |
EUR 1096 |
- Category: PiggyBac Technology
|
PB-Cuo-shMCS-IRES-GFP-EF1-CymR-Puro Inducible shRNA Cloning and Expression Vector |
PBQMSH812A-1 |
SBI |
10 ug |
EUR 1096 |
- Category: PiggyBac Technology
|
PB-SV40-Neo-EF1-GFP-CAGs-cMyc-Klf4-Oct4-Sox2 Mouse 4-in-1 iPSC Vector |
PB400A-1 |
SBI |
10 ug |
EUR 1229 |
- Category: PiggyBac Technology
|
10 L DMEM (DULBECCO'S MODIFICATION OF EAGLE'S MEDIUM), POWDER WITH 4.5 G/L GLUCOSE, L-GLUTAMINE, AND SODIUM PYRUVATE WITHOUT SODIUM BICARBONATE |
50-003-PB |
CORNING |
10 L/pk |
EUR 65 |
Description: Media Catalog; Classical Media |
10 L MEM (MINIMUM ESSENTIAL MEDIUM), POWDER WITH EARLE'S SALTS AND L-GLUTAMINE, WITHOUT SODIUM BICARBONATE |
50-010-PB |
CORNING |
10 L/pk |
EUR 64 |
Description: Media Catalog; Classical Media |
10 L MEM (MINIMUM ESSENTIAL MEDIUM), POWDER WITH EARLE'S SALTS, L-GLUTAMINE, AND NONESSTENTIAL AMINO ACIDS WITHOUT SODIUM BICARBONATE |
50-011-PB |
CORNING |
10 L/pk |
EUR 65 |
Description: Media Catalog; Classical Media |
10 L DMEM (DULBECCO'S MODIFICATION OF EAGLE'S MEDIUM), POWDER WITH 4.5 G/L GLUCOSE AND L-GLUTAMINE, WITHOUT SODIUM BICARBONATE AND SODIUM PYRUVATE |
50-013-PB |
CORNING |
10 L/pk |
EUR 58 |
Description: Media Catalog; Classical Media |
10 L ISCOVE'S MODIFCATION OF DMEM WITH L-GLUTAMINE, 25 MM HEPES WITHOUT Α-THIOGLYCEROL, Β-MERCAPTOETHANOL, SODIUM BICARBONATE |
50-016-PB |
CORNING |
10 L/pk |
EUR 124 |
Description: Media Catalog; Classical Media |
10 L RPMI 1640, POWDER WITH L-GLUTAMINE, WITHOUT SODIUM BICARBONATE |
50-020-PB |
CORNING |
10 L/pk |
EUR 60 |
Description: Media Catalog; Classical Media |
10 L HAM'S F-12 MEDIUM, POWDER WITH L-GLUTAMINE WITHOUT SODIUM BICARBONATE |
50-040-PB |
CORNING |
10 L/pk |
EUR 64 |
Description: Media Catalog; Classical Media |
10 L MEDIUM 199 (MOD.), POWDER WITH EARLE'S SALTS AND L-GLUTAMINE WITHOUT SODIUM BICARBONATE |
50-050-PB |
CORNING |
10 L/pk |
EUR 65 |
Description: Media Catalog; Classical Media |
10 L HBSS (HANK'S BALANCED SALT SOLUTION), POWDER WITHOUT SODIUM BICARBONATE, CALCIUM, MAGNESIUM, AND PHENOL RED |
55-022-PB |
CORNING |
10 L/pk |
EUR 71 |
Description: Media Catalog; Buffered Salt-Salution |
10 L DPBS (DULBECCO'S PHOSPHATE-BUFFERED SALINE), POWDER WITHOUT CALCIUM AND MAGNESIUM |
55-031-PB |
CORNING |
10 L/pk |
EUR 55 |
Description: Media Catalog; Buffered Salt-Salution |
pCT-Mem-GFP (pMSCV, Plasma Membrane, Neuromodulin Tag) |
CYTO100-PB-1 |
SBI |
10 ug |
EUR 684 |
- Category: Bioluminescent Imaging
|
pCT-InnerMem-GFP (pMSCV, Inner Leaflet Plasma of Membrane, Farnesylation signal Tag) |
CYTO101-PB-1 |
SBI |
10 ug |
EUR 684 |
- Category: Bioluminescent Imaging
|
pCT-Mito-GFP (pMSCV, Mitochondria, COX8 Tag) |
CYTO102-PB-1 |
SBI |
10 ug |
EUR 684 |
- Category: Bioluminescent Imaging
|
pCT-Pero-GFP (pMSCV, Peroxisome, Peroxisome consensus Tag) |
CYTO108-PB-1 |
SBI |
10 ug |
EUR 684 |
- Category: Bioluminescent Imaging
|
pCT-Actin-GFP (pMSCV, Cytoskeleton, B-actin Tag) |
CYTO110-PB-1 |
SBI |
10 ug |
EUR 684 |
- Category: Bioluminescent Imaging
|
pCT-Tublin-GFP (pMSCV, Cytoskeleton, alpha-tubulin Tag) |
CYTO111-PB-1 |
SBI |
10 ug |
EUR 684 |
- Category: Bioluminescent Imaging
|
pCT-H2B-GFP (pMSCV, Nucleus, H2B Tag) |
CYTO113-PB-1 |
SBI |
10 ug |
EUR 684 |
- Category: Bioluminescent Imaging
|
pCT-Cyto-GFP (pMSCV, Cytosol, Untagged) |
CYTO118-PB-1 |
SBI |
10 ug |
EUR 684 |
- Category: Bioluminescent Imaging
|
pCT-Cyto-GFPLuc (pMSCV, Cytosol, GFP+Luciferase Untagged) |
CYTO121-PB-1 |
SBI |
10 ug |
EUR 684 |
- Category: Bioluminescent Imaging
|
10 L MEM (MINIMUM ESSENTIAL MEDIUM), POWDER WITH EARLE'S SALTS, WITHOUT L-GLUTAMINE, PHENOL RED, SODIUM BICARBONATE |
90-009-PB |
CORNING |
10 L/pk |
EUR 70 |
Description: Media Catalog; Classical Media |
10 L DMEM (DULBECCO'S MODIFICATION OF EAGLE'S MEDIUM), POWDER WITH 4.5 G/L GLUCOSE WITHOUT SODIUM BICARBONATE, L-GLUTAMINE, SODIUM PYRUVATE, AND PHENOL RED |
90-013-PB |
CORNING |
10 L/pk |
EUR 65 |
Description: Media Catalog; Classical Media |
10 L RPMI 1640, POWDER WITHOUT L-GLUTAMINE, PHENOL RED, AND SODIUM BICARBONATE |
90-022-PB |
CORNING |
10 L/pk |
EUR 65 |
Description: Media Catalog; Classical Media |
10 L MEDIUM 199 (MOD.), POWDER WITH EARLE'S SALTS WITHOUT SODIUM BICARBONATE, L-GLUTAMINE, AND PHENOL RED |
90-050-PB |
CORNING |
10 L/pk |
EUR 78 |
Description: Media Catalog; Classical Media |
10 L DMEM (DULBECCO'S MODIFICATION OF EAGLE'S MEDIUM)/HAM'S F-12 50/50 MIX, POWDER WITHOUT SODIUM BICARBONATE, L-GLUTAMINE, AND PHENOL RED |
90-090-PB |
CORNING |
10 L/pk |
EUR 68 |
Description: Media Catalog; Classical Media |
10 L DMEM (DULBECCO'S MODIFICATION OF EAGLE'S MEDIUM)/HAM'S F-12 50/50 MIX, POWDER WITHOUT SODIUM BICARBONATE AND L-GLUTAMINE |
90-091-PB |
CORNING |
10 L/pk |
EUR 69 |
Description: Media Catalog; Classical Media |
10 L DMEM (DULBECCO'S MODIFICATION OF EAGLE'S MEDIUM), POWDER WITHOUT SODIUM BICARBONATE, GLUCOSE, L-GLUTAMINE, SODIUM PYRUVATE, AND PHENOL RED |
90-113-PB |
CORNING |
10 L/pk |
EUR 66 |
Description: Media Catalog; Classical Media |
Anti-Hu CD15 Pacific Blue |
PB-138-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD15 Pacific Blue |
PB-138-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD45 Pacific Blue |
PB-160-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD193 Pacific Blue |
PB-161-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD3 Pacific Blue |
PB-202-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD3 Pacific Blue |
PB-202-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD6 Pacific Blue |
PB-205-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD6 Pacific Blue |
PB-205-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD7 Pacific Blue |
PB-206-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD7 Pacific Blue |
PB-206-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD8 Pacific Blue |
PB-207-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD8 Pacific Blue |
PB-207-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD9 Pacific Blue |
PB-208-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD9 Pacific Blue |
PB-208-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD10 Pacific Blue |
PB-209-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD10 Pacific Blue |
PB-209-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD15 Pacific Blue |
PB-213-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD15 Pacific Blue |
PB-213-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD25 Pacific Blue |
PB-218-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD25 Pacific Blue |
PB-218-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD29 Pacific Blue |
PB-219-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD29 Pacific Blue |
PB-219-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD43 Pacific Blue |
PB-220-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD43 Pacific Blue |
PB-220-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD44 Pacific Blue |
PB-221-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD44 Pacific Blue |
PB-221-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD45 Pacific Blue |
PB-222-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD45 Pacific Blue |
PB-222-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD45RA Pacific Blue |
PB-223-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD45RA Pacific Blue |
PB-223-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD47 Pacific Blue |
PB-225-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD47 Pacific Blue |
PB-225-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD48 Pacific Blue |
PB-226-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD48 Pacific Blue |
PB-226-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD53 Pacific Blue |
PB-227-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD53 Pacific Blue |
PB-227-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD59 Pacific Blue |
PB-233-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD59 Pacific Blue |
PB-233-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD71 Pacific Blue |
PB-235-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD71 Pacific Blue |
PB-235-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD31 Pacific Blue |
PB-273-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD31 Pacific Blue |
PB-273-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD80 Pacific Blue |
PB-287-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD80 Pacific Blue |
PB-287-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD14 Pacific Blue |
PB-293-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD14 Pacific Blue |
PB-293-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-HLA-DR/DP Pacific Blue |
PB-296-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-HLA-DR/DP Pacific Blue |
PB-296-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD34 Pacific Blue |
PB-297-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD34 Pacific Blue |
PB-297-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD105 Pacific Blue |
PB-298-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD105 Pacific Blue |
PB-298-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD19 Pacific Blue |
PB-305-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD19 Pacific Blue |
PB-305-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD21 Pacific Blue |
PB-306-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD21 Pacific Blue |
PB-306-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD27 Pacific Blue |
PB-308-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD27 Pacific Blue |
PB-308-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD41 Pacific Blue |
PB-309-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD41 Pacific Blue |
PB-309-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD177 Pacific Blue |
PB-314-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD177 Pacific Blue |
PB-314-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu IgM Pacific Blue |
PB-320-C100 |
ExBio |
0.1 mg |
EUR 238 |
Anti-Hu CD46 Pacific Blue |
PB-342-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD46 Pacific Blue |
PB-342-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD4 Pacific Blue |
PB-359-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD4 Pacific Blue |
PB-359-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD33 Pacific Blue |
PB-365-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD33 Pacific Blue |
PB-365-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD38 Pacific Blue |
PB-366-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD38 Pacific Blue |
PB-366-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD52 Pacific Blue |
PB-368-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD52 Pacific Blue |
PB-368-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD20 Pacific Blue |
PB-414-T025 |
ExBio |
25 tests |
EUR 154 |
Anti-Hu CD20 Pacific Blue |
PB-414-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-Hu CD41a Pacific Blue |
PB-417-T100 |
ExBio |
100 tests |
EUR 269 |
Anti-HLA-DR Pacific Blue |
PB-474-T025 |
ExBio |
25 tests |
EUR 154 |
This problem-solving innovation in regulation triggered by the latest epidemiologic disaster in South Korea demonstrates the emergence of the precision regulation strategy. South Korea has applied streamlined fast-track providers for the biotechnology business to provide check kits swiftly. This text expands the definition of precision regulation from AI regulation literature, and positions the time period as a brand new regulatory rationale, not as a regulatory device, utilizing the case examine from South Korea.